Comments
Dendreon CEO: rival prostate drugs to boost market
13.03.2012. | (Reuters) - Dendreon Corp expects the entry of rival prostate cancer drugs from Johnson & Johnson and Medivation Inc to boost demand for new therapies, including its own Provenge, the company's new chief executive said....
